Newly-released Large Molecule Bioanalytical Testing Service industry analysis report by Future Market Insights reveals that global sales of Large Molecule Bioanalytical Testing Market in 2022 were held at USD 1.3 Billion. With a CAGR of 12.1% from 2023 to 2033, the market is projected to reach USD 4.7 Billion by 2033. Clinical Phase is expected to generate significant revenue and is projected to grow at a CAGR of 10.9% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Market Size (2023) | USD 1.5 Billion |
| Global Market Size (2033) | USD 4.7 Billion |
| Global Market Size CAGR (2023 to 2033) | 12.1% |
| USA Market Size CAGR (2023 to 2033) | 12.3% |
| Key Companies Profiled | Covance; IQVIA; Syneos Health; SGS SA; Toxikon; Intertek Group plc; Pace Analytical Services LLC; ICON Plc; Charles River Laboratories; Thermo Fisher Scientific |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
As per the Large Molecule Bioanalytical Testing Service industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Large Molecule Bioanalytical Testing Service industry increased at around 11.9% CAGR, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held significant share in the global market.
The increase in demand for forward-looking and high-grade large molecule bioanalytical testing services is expected to propel the market forward. Reduced time to market, increased regulatory observation, and a high risk of product failure are a few of the factors driving the demand for large molecule bioanalytical testing services. Owing to this, the Large Molecule Bioanalytical Testing Service market is projected to grow at a CAGR of 12.1% over the coming 10 years.
Because of rising healthcare expenditures, there is a greater need for high-quality care. The demand for analytical testing is developing in response to new pharmaceutical product advancements. Due to increased competition in the healthcare business and rising pricing concerns, many companies are turning to outsourcing services for analytical testing.
The demand for analytical testing has increased as research and development activities for new medication development, combination products, and other complex medicines have increased.
With the prevalence of HIV, infectious illnesses, and other disorders, the demand for bioanalytical testing services has shot up in the recent past. Furthermore, enhanced government actions to control the spread of infectious diseases like Corona and the Ebola virus are expected to assist the business. As a result, the market is expected to grow throughout the assessment period.
Throughout the projection period, increased research activities and the presence of a vast pipeline of peptides, biologics, and amino acid-based compounds are expected to move the market ahead. Bioanalysis of large molecules also involves the utilization of highly skilled professionals as well as analytical gear and infrastructure.
With a CAGR of 12.3% during the projected period, Large Molecule Bioanalytical Testing Service revenue is expected to grow at a significant pace in North America. Because of the rising frequency of numerous chronic diseases and the growing use of large-molecule medicines as an alternative to small molecules, the United States has the largest market share.
According to the International Diabetic Federation Report 2019, the United States has a diabetic population of 49 million geriatrics, which has resulted in an increase in demand for bioanalysis of new peptide therapies such as glucagon-like peptide 1. As a result, the market is likely to grow throughout the forecast period. Furthermore, the presence of large firms in the region aided market expansion.
As one of the main production hubs for highly dependable, complicated, and high-end pharmaceuticals, the USA accounted for a significant share of the global market in 2022. The market is likely to be driven by rapid technology improvements and increasing demand for bioanalytical testing services. Furthermore, because of the country's developing healthcare business, biopharmaceutical companies are focusing on the USA market.
The market in the United kingdom is expected to reach a valuation of USD 180.6 Million by 2033. Growing with a CAGR of 12.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around USD 127 Million.
In Japan, the market is expected to grow at a CAGR of 10.8% from 2023 to 2033, reaching around USD 161 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of USD 104 Million during the forecast period.
The market in South Korea is expected to reach a valuation of around USD 123 Million by 2033, growing at a CAGR of 12.6% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around USD 85 Million.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The clinical segment is expected to grow at a CAGR of 10.9%. Based on the study phase, the market is segmented into preclinical and clinical. The rising frequency of chronic diseases and the growing demand for clinical trials in developing countries are likely to propel the segment forward.
The market through Antidrug Antibodies (ADA) is expected to grow at a CAGR of 11.8% during the forecast period. Large-molecule drug development is aided by ADA assays. Antibodies against large molecule medications, such as antibody or protein therapies, are produced by the immune system. As a result, ADAs can be detected using ADA tests. Patients who create an antibody response will have a variety of reactions, ranging from life-threatening to no clinical implications. This can lead to anaphylactic shock, allergic responses, or autoimmunity, among other things.
Pharmacokinetic expert services are carried out in accordance with GCP specifications as well as international regulatory rules. Moreover, clinical trials for biologics and biosimilars include a trial to measure the concentration of this drug in healthy volunteers.
The ELISA or MSD platform is used to offer this service. A commonly utilized immunoassay for the detection of significant in vitro pharmacokinetic research is ELISA. In line with the chemical construction and principle of operation of drug substances, antibody sensitivity in pharmacokinetic immunoanalysis should always be fixed.
The key players operating in the Large Molecule Bioanalytical Testing Services Market include Covance, IQVIA, Syneos Health, SGS SA, Toxikon, Intertek Group plc, Pace Analytical Services LLC, ICON Plc, Charles River Laboratories, and Thermo Fisher Scientific.
Few of the recent developments of key Large Molecule Bioanalytical Testing Service providers are as follows:
Similarly, recent developments related to companies in the Large Molecule Bioanalytical Testing Services have been tracked by the team at Future Market Insights, which are available in the full report.
The market is valued at USD 1.5 billion in 2023.
The growth potential of the market is 12.1% through 2033.
The South Korea market is expected to expand at a CAGR of 12.6% through 2033.
Covance, IQVIA, and Syneos Health are the top players.
Key players are introducing new production facilities.
Explore Healthcare Services Insights
View Reports
Large Molecule Bioanalytical Testing Services Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
